Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma
| Autor: | Ashkan, Lashkari, Warren A, Chow, Frances, Valdes, Lucille, Leong, Vu, Phan, Przemyslaw, Twardowski, Neena, Kapoor, Arturo, Molina, Zaid, Al-Kadhimi, Paul, Frankel, George, Somlo |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Bone Neoplasms Sarcoma Ewing Protective Agents Transplantation Autologous Immunoenzyme Techniques Young Adult Antineoplastic Combined Chemotherapy Protocols Rhabdomyosarcoma Humans Ifosfamide Neuroectodermal Tumors Primitive Peripheral Prospective Studies Melphalan Mesna Neoplasm Staging Osteosarcoma Remission Induction Hematopoietic Stem Cell Transplantation Sarcoma Prognosis Combined Modality Therapy Survival Rate Treatment Outcome Doxorubicin Disease Progression Feasibility Studies Female Cisplatin Neoplasm Recurrence Local Safety |
| Zdroj: | Anticancer research. 29(8) |
| ISSN: | 1791-7530 |
| Popis: | Patients with locally advanced or metastatic/recurrent soft tissue and Ewing's sarcoma (EWS) have few treatment options. The purpose of our phase II study was to assess the feasibility, safety and efficacy of tandem high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) in such patients.Thirteen patients were enrolled onto this study. The first cycle of HDCT consisted of doxorubicin (150 mg/m(2)) and ifosfamide (14 g/m(2)) mixed with mesna (14 g/m(2)), while the second cycle consisted of melphalan (150 mg/m(2)) and cisplatin (200 mg/m(2)).Eleven out of 13 patients were able to complete both cycles of HDCT. No treatment-related mortality occurred and grade 3 or 4 toxicity was clinically tolerable. The 5-year progression-free survival (PFS) and overall survival (OS) for all patients was 23% (confidence interval, CI: 0-46%) and 31% (CI: 14-70%), respectively. Out of the four patients still alive, two had EWS and measurable disease at the time of ASCT and achieved a complete remission, remaining progression free 126 and 155 months after ASCT.Our study demonstrates the feasibility and safety of tandem HDCT in patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term PFS and OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|